03:48 PM EST - Amorfix Life Sciences Ltd. : announced that it has completed initial steps in the generation of a blood test for the diagnosis of ALS. Using a proprietary antibody in a simple ELISA assay, the Company is able to detect and measure misfolded superoxide dismutase 1 (SOD1) added into human plasma. Misfolded SOD1 is thought to have an important role in the pathogenesis of both familial and sporadic ALS. Amorfix Life Sciences Ltd.
shares T.AMF are trading up $0.015 at $0.38.
